Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies
Prevention
Management
Recommendation Grading
Overview
Title
Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies
Authoring Organizations
American Society of Clinical Oncology
Multinational Association of Supportive Care in Cancer
Publication Month/Year
July 16, 2021
Last Updated Month/Year
September 3, 2024
Supplemental Implementation Tools
Document Type
Guideline
Country of Publication
US
Document Objectives
To provide evidence-based recommendations for prevention and management of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies.
Target Patient Population
Adult patients with cancer who are scheduled to receive or who have received nonsurgical cancer therapy.
Target Provider Population
Oncologists and other physicians, dentists, dental specialists, dental hygienists, oncology nurses, clinical researchers, advanced practitioners, and patients with cancer
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Outpatient, Radiology services
Intended Users
Dentist, nurse, nurse practitioner, physician, physician assistant
Scope
Management, Prevention
Diseases/Conditions (MeSH)
D014987 - Xerostomia, D018987 - Salivary Ducts, D012469 - Salivary Glands
Keywords
head and neck cancer, Head and Neck Carcinomas, salivary gland malignancy, xerostomia, salivary gland
Source Citation
Mercadante V, Jensen SB, Smith DK, Bohlke K, Bauman J, Brennan MT, Coppes RP, Jessen N, Malhotra NK, Murphy B, Rosenthal DI, Vissink A, Wu J, Saunders DP, Peterson DE. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline. J Clin Oncol. 2021 Sep 1;39(25):2825-2843. doi: 10.1200/JCO.21.01208. Epub 2021 Jul 20. PMID: 34283635.